| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Joseph M Lane | |
| Eve Donnelly | |||
| Aasis Unnanuntana | |||
| Brian P Gladnick | |||
| P2860 | cites work | FRAX and the assessment of fracture probability in men and women from the UK | Q24654123 |
| Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. | Q33979879 | ||
| Intravenous zoledronic acid in postmenopausal women with low bone mineral density | Q34116443 | ||
| Osteoporosis prevention, diagnosis, and therapy | Q34140339 | ||
| Preanalytical variability of biochemical markers of bone turnover. | Q34148390 | ||
| Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs | Q34148410 | ||
| Biochemical markers of bone turnover: part I: biochemistry and variability | Q34239361 | ||
| Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. | Q34319046 | ||
| History of the Rochester Epidemiology Project | Q34374377 | ||
| Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study | Q34404537 | ||
| Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q34409983 | ||
| Relationship of bone turnover to bone density and fractures | Q34430413 | ||
| Identification of osteopenic women at high risk of fracture: the OFELY study. | Q34450708 | ||
| Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial | Q34485941 | ||
| Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? | Q34505373 | ||
| Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. | Q34590956 | ||
| Diagnosis of osteoporosis and assessment of fracture risk | Q34678969 | ||
| Clinical use of bone densitometry: scientific review | Q34959589 | ||
| Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis | Q35053491 | ||
| Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture | Q35066807 | ||
| Perspective. How many women have osteoporosis? | Q35437028 | ||
| Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis | Q36024459 | ||
| Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study | Q36596562 | ||
| Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures | Q36598613 | ||
| Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model | Q36648725 | ||
| Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases | Q36662494 | ||
| The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. | Q36745467 | ||
| Secular trends in hip fracture incidence and recurrence | Q37149034 | ||
| Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring | Q37176381 | ||
| Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club | Q37250572 | ||
| New guidelines for the prevention and treatment of osteoporosis | Q37367222 | ||
| Bone turnover markers: understanding their value in clinical trials and clinical practice | Q37384765 | ||
| FRAX and its applications to clinical practice | Q37386027 | ||
| Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial | Q38439289 | ||
| FRAX and risk of vertebral fractures: the fracture intervention trial | Q39981967 | ||
| Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women | Q40215055 | ||
| A meta-analysis of previous fracture and subsequent fracture risk | Q40494142 | ||
| Bone mineral density thresholds for pharmacological intervention to prevent fractures | Q40508494 | ||
| Improvement in the undertreatment of osteoporosis following hip fracture. | Q40639571 | ||
| Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis | Q40664389 | ||
| Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy | Q41087577 | ||
| Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. | Q42646024 | ||
| Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation | Q43583991 | ||
| Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy | Q43842238 | ||
| Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs | Q43917199 | ||
| Hip fracture patients are not treated for osteoporosis: a call to action | Q44274966 | ||
| Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. | Q44440820 | ||
| Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography | Q44578541 | ||
| Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. | Q44767883 | ||
| Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro | Q44768465 | ||
| Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. | Q44961457 | ||
| Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture | Q45012920 | ||
| Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk | Q45023627 | ||
| [Bone metabolic marker for osteoporosis]. | Q46016712 | ||
| Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis | Q46065460 | ||
| The management of osteoporosis following hip fracture: Have we improved our care? | Q47432571 | ||
| Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. | Q51115984 | ||
| Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. | Q51554777 | ||
| Interlaboratory variation of biochemical markers of bone turnover. | Q53323576 | ||
| Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. | Q55033830 | ||
| International variations in hip fracture probabilities: implications for risk assessment | Q57215208 | ||
| Hormone Replacement Therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral Density | Q57224710 | ||
| Serum osteocalcin has limited usefulness as a diagnostic marker for rickets | Q58641875 | ||
| Use of Bone Turnover Markers in the Real World: Are We There Yet? | Q60777446 | ||
| Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing | Q67504223 | ||
| Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women | Q67967028 | ||
| Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989 | Q68103553 | ||
| Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis | Q68825001 | ||
| Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption | Q71070718 | ||
| Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion | Q71877366 | ||
| The short-term effects of conjugated estrogen on bone turnover in older women | Q72095088 | ||
| Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays | Q72588368 | ||
| Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly | Q72664702 | ||
| The diagnosis of osteoporosis | Q72846752 | ||
| Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment | Q72879099 | ||
| Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study | Q73420596 | ||
| Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption | Q73995291 | ||
| Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study | Q74141058 | ||
| Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis | Q74242371 | ||
| Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study | Q75363746 | ||
| Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase | Q77372280 | ||
| Correlation of femoral and lumbar DXA and calcaneal ultrasound, measured in situ with intact soft tissues, with the in vitro failure loads of the proximal femur | Q77746279 | ||
| Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents | Q77878009 | ||
| Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy | Q79184483 | ||
| [Biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP)] | Q79323388 | ||
| Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study | Q79774734 | ||
| Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients | Q79935930 | ||
| Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer | Q80931543 | ||
| Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial | Q81235380 | ||
| Transient osteoporosis | Q81714727 | ||
| Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis | Q81730772 | ||
| FRAX facts | Q83642166 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone fracture | Q68833 |
| P304 | page(s) | 743-753 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Journal of Bone and Joint Surgery | Q6294867 |
| P1476 | title | The assessment of fracture risk | |
| P478 | volume | 92 |
| Q36683987 | A guide to improving the care of patients with fragility fractures |
| Q91436341 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q64084429 | Advanced Genetic Approaches in Discovery and Characterization of Genes Involved With Osteoporosis in Mouse and Human |
| Q31141102 | Advances in imaging approaches to fracture risk evaluation |
| Q39264339 | Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up |
| Q47644335 | Are DXA/aBMD and QCT/FEA Stiffness and Strength Estimates Sensitive to Sex and Age? |
| Q92270659 | Bone Turnover Markers and Bone Mineral Density to Predict Osteoporotic Fractures in Older Women: A Retrospective Comparative Study |
| Q47608253 | Bone and the Immune System |
| Q38022220 | Bone health and multiple sclerosis |
| Q28066185 | Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice |
| Q91966323 | Comparative proteomics analysis of microvesicles in human serum for the evaluation of osteoporosis |
| Q37407747 | Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures |
| Q30909324 | Comparison between frailty index of deficit accumulation and phenotypic model to predict risk of falls: data from the global longitudinal study of osteoporosis in women (GLOW) Hamilton cohort |
| Q49337875 | Comparison of bone mineral density among pre- and post-menopausal women with and without chronic generalized periodontitis |
| Q88404467 | Comparison of femur stiffness measured from DXA and QCT for assessment of hip fracture risk |
| Q91863790 | Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients |
| Q47762656 | Concise Review: Musculoskeletal Stem Cells to Treat Age-Related Osteoporosis. |
| Q101226611 | Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis |
| Q91902618 | Environmentally-Controlled Near Infrared Spectroscopic Imaging of Bone Water |
| Q51758341 | Epidemiology of hip fracture in nursing home residents with multiple sclerosis. |
| Q36644255 | Ethnic differences in composite indices of femoral neck strength. |
| Q89719475 | Evaluating the Performance of the WHO International Reference Standard for Osteoporosis Diagnosis in Postmenopausal Women of Varied Polygenic Score and Race |
| Q36695918 | Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT. |
| Q50785762 | Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride. |
| Q38777571 | Expert Consensus on the Management of Patients with Postmenopausal Osteoporosis in the Spanish Healthcare System. |
| Q36356633 | Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate. |
| Q92003654 | Hip fractures in the elderly without osteoporosis |
| Q58118044 | How to Build a Kidney Stone Prevention Clinic |
| Q92342523 | Increased pore size of scaffolds improves coating efficiency with sulfated hyaluronan and mineralization capacity of osteoblasts |
| Q47151774 | International Classification of Diseases (ICD)-coded obesity predicts risk of incident osteoporotic fracture |
| Q53053004 | Intravenous contrast injection significantly affects bone mineral density measured on CT. |
| Q64087884 | Is there a correlation between outcomes after hip arthroscopy for femoroacetabular impingement syndrome and patient cortical bone thickness? |
| Q55645996 | Juvenile bovine bone is an appropriate surrogate for normal and reduced density human bone in biomechanical testing: a validation study. |
| Q50111162 | Loss of skeletal muscle mass in patients with chronic liver disease is related to decrease in bone mineral density and exercise tolerance |
| Q64900969 | Low Hemoglobin Is Associated With Low Bone Mineral Density and High Risk of Bone Fracture in Male Adults: A Retrospective Medical Record Review Study. |
| Q89486107 | Low bone mineral density is associated with hypogonadism and cranial irradiation in male childhood cancer survivors |
| Q38682373 | Micro Finite Element models of the vertebral body: Validation of local displacement predictions |
| Q92189057 | Microdamage as a Bone Quality Component: Practical Guidelines for the Two-Dimensional Analysis of Linear Microcracks in Human Cortical Bone |
| Q50052201 | Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker. |
| Q39430936 | Multicenter analysis of CIREN occupant lumbar bone mineral density and correlation with age and fracture incidence |
| Q38783911 | Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study. |
| Q38041419 | Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q36564425 | Osteoporosis: now and the future |
| Q90729947 | Patient Age Is Inversely Associated with Injury Counts Caused by Motor Vehicle Crashes |
| Q57074439 | Pharmacological and Non-pharmacological Means for Prevention of Fractures among Elderly |
| Q83364079 | Poor bone microarchitecture in older men with impaired physical performance--the STRAMBO study |
| Q38725697 | Population Pharmacokinetic and Exposure-Response Analysis of Weekly Teriparatide in Osteoporosis Patients |
| Q38836713 | Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know. |
| Q64079134 | Predicting fracture risk in patients with chronic obstructive pulmonary disease: a UK-based population-based cohort study |
| Q33714110 | Predicting hip and major osteoporotic fractures using administrative data |
| Q48266112 | Prediction of major osteoporotic and hip fractures in Australian men using FRAX scores adjusted with trabecular bone score |
| Q92135029 | Prevalence and risk factors for osteoporotic fracture among adults with comorbidities in Al-Ahsaa, Saudi Arabia |
| Q38641391 | Quantitative two-dimensional ultrashort echo time magnetization transfer (2D UTE-MT) imaging of cortical bone |
| Q92679842 | Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis a |
| Q85025614 | Risk factors for peripheral fractures vary by age in older men--the prospective MINOS study |
| Q64094410 | Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review |
| Q90725243 | Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk |
| Q35078755 | Short-term and long-term orthopaedic issues in patients with fragility fractures |
| Q92059853 | Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update |
| Q34111381 | Surgical preferences of patients at risk of hip fractures: hemiarthroplasty versus total hip arthroplasty |
| Q90468437 | The Correlation between Trabecular Bone Score and Lumbar Spine Bone Mineral Density in Patients with Normal and High Body Mass Index |
| Q55279750 | The Effectiveness of Osteoporosis Screening and Treatment in the Midwest. |
| Q90192779 | The Influence of Thyroid Pathology on Osteoporosis and Fracture Risk: A Review |
| Q55005153 | The Potential Role of miRNAs as New Biomarkers for Osteoporosis. |
| Q55196506 | The effect of Chinese martial arts Tai Chi Chuan on prevention of osteoporosis: A systematic review. |
| Q35613775 | The effect of long-term alendronate treatment on cortical thickness of the proximal femur |
| Q54713523 | The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly. |
| Q39324995 | The prevalence and risk factors for osteoporosis among 18- to 49-year-old Turkish women |
| Q39412975 | The relationship between protein quantity, BMD and fractures in older adults. |
| Q35512739 | Thoracic and lumbar vertebral bone mineral density changes in a natural occurring dog model of diffuse idiopathic skeletal hyperostosis |
| Q39182256 | Vertebral Body Compression Fractures and Bone Density: Automated Detection and Classification on CT Images |
| Q36062140 | Weak cation exchange magnetic beads coupled with matrix-assisted laser desorption ionization-time of flight-mass spectrometry in screening serum protein markers in osteopenia |
Search more.